Bio-Rad Laboratories Inc (NYSE: BIO) has reported earnings for its third fiscal quarter (ending September 30) of $23.37 versus $3.65 for the same period a year ago — an increase of 540%. E.P.S. were $-27.74 for the latest four quarters through September 30 versus $-5.74 for the same period a year ago — an increase of 383%.
Recent Price Action
On 10/30/24, Bio-Rad Laboratories Inc (NYSE: BIO) stock declined slightly by -0.3%, closing at $330.58. However, this decline was accompanied by below average trading volume at 70% of normal. The stock has performed in line with the market over the last nine months and has declined -2.7% during the last week.
Current PriceTarget Research Rating
BIO is expected to be a modest Value Builder reflecting capital returns that are forecasted to exceed the cost of capital.
Bio-Rad Laboratories has a current Value Trend Rating of C (High Neutral). The Value Trend Rating reflects inconsistent signals from PTR’s two proprietary measures of a stock’s attractiveness. Bio-Rad Laboratories has a good Appreciation Score of 79 but a neutral Power Rating of 41, producing the High Neutral Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment